Superworth

Veracyte EPS VCYT

Diluted earnings per share by quarter and over the last twelve months, from 2012.

Last 12 months, to Jun 30, 2026
$1.40
Latest quarter, Q2 FY26
$0.31
Fiscal year 2025
$0.82
+173% on the year before

Veracyte's earnings per share was $1.40 over the twelve months to Jun 30, 2026, up 324% on a year earlier.

In its latest quarter, Q2 FY26, it was $0.31.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025$0.82+173%
FY2024$0.30n/a
FY2023−$1.03n/a
FY2022−$0.50n/a
FY2021−$1.14n/a
FY2020−$0.68n/a
FY2019−$0.27n/a
FY2018−$0.65n/a
FY2017−$0.91n/a
FY2016−$1.10n/a
FY2015−$1.30n/a
FY2014−$1.36n/a
FY2012n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26$0.31n/a$1.40
Q1 FY26$0.35+289%$1.08
Q4 FY25$0.50+733%$0.82
Q3 FY25$0.24+26%$0.38
Q2 FY25−$0.01−114%$0.33
Q1 FY25$0.09n/a$0.41
Q4 FY24$0.06n/a$0.30
Q3 FY24$0.19n/a−$0.15
Q2 FY24$0.07n/a−$0.75
Q1 FY24−$0.02n/a−$0.94
Q4 FY23−$0.39n/a−$1.03
Q3 FY23−$0.41n/a−$0.69

Against its peers

Companies in Medical - Diagnostics & Research nearest Veracyte's size, closest first, today.

CompanyEPS, 12 monthsGrowth
VCYTVeracyte$1.40+324% a year
CDNACareDx$2.07+116% a year
BLLNBillionToOne$0.65
LNTHLantheus$4.13+10% a year
CAICaris Life Sciences$0.37
BIOBio-Rad Laboratories$8.25−30% a year
RVTYRevvity$2.10−11% a year
MEDPMedpace$17.05+27% a year
LHLabcorp$12.09+33% a year
DGXQuest Diagnostics$9.41+18% a year
NRCNRC Health$0.25−67% a year
Peer median$3.12

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Veracyte

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.